KC
RNTX

Kepos Capital’s Rein Therapeutics RNTX Stock Holding History

Kepos Capital’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-106,000
Closed -$294K – 248
2024
Q2 		$294K Buy
+106,000
New +$436K 0.11% 66

Other funds holding RNTX

UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Kepos Capital's RNTX Position: Q3 2024 in Review

Kepos Capital sold out of Rein Therapeutics (RNTX) in Q3 2024, closing a stake of 106,000 shares — an estimated $294K sold.

Kepos Capital first reported a position in RNTX in Q2 2024 and held it in 1 quarter. The position peaked at $294K in Q2 2024. 32 funds tracked by Wall St. Rank hold RNTX as of Q3 2024.

  • Kepos Capital reported no remaining Rein Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Kepos Capital sold 106,000 Rein Therapeutics shares in Q3 2024, an estimated $294K.
  • Kepos Capital first reported a position in Rein Therapeutics in Q2 2024 and held it in 1 quarter.
  • Kepos Capital's Rein Therapeutics position peaked at $294K in Q2 2024.
  • 32 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2024.

Based on Kepos Capital's 13F filing for Q3 2024, filed 12 Nov 2024.